Von der Studienplanung bis zur Nutzenbewertung: Mit oder ohne pharmazeutische Industrie?

Abstract

The financing of clinical studies by the pharmaceutical industry is a controversial topic both internationally and in here in Germany. The well-known unacceptable shortcomings require no further confirmation. It is, however, indisputable that the pharmaceutical industry and medical science are co-dependent. Neither the marketing of industrial products nor the research and education of clinical scientists could function without this cooperation. Therefore, all partners need suggestions concerning goal orientation and consensus. The aim of this discussion is to formulate just such suggestions. To structure this discussion, we have raised the following questions: Must we always be suspicious of the results of studies financed by the pharmaceutical industry? We have to keep in mind that in Germany all clinical trials leading to approval of a drug were supported by the industry. What, exactly, do we want to achieve with our explicit and often justified criticism of these studies? What should be done to achieve a higher validity of the published data if we avoid answering the decisive question of whether we accept the challenge of continuing to let research and teaching be financed by the pharmaceutical industry or reject this kind of cooperation and support altogether.

Leserbrief zur Stellungnahme von Medizinstudenten und deren Dozenten des Wochenendseminars „Bewertung des Nutzens von Gesundheitsleistungen“ Universität Ulm, 13.-15. Mai 2011 zum Aufsatz Die „Gute Praxis Gesundheitsinformation“

“…In jedem Fall besteht ein Sachverhalt, der das Risiko eines verzerrten Urteils erhöht, also ein Interessenkonflikt. Ganz in Übereinstimmung mit Porszolt [7] bin ich der Meinung, dass wir zielführende und wissenschaftlich gestützte, also evidenzbasierte Strategien und Maßnahmen entwickeln müssen, um unvermeidbare Interessenkonflikt zu regulieren. Unser Wissen darüber, was funktioniert und was nicht, ist lückenhaft.…”